These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22465318)

  • 1. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
    Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R
    Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy.
    Hosoda J; Ishikawa T; Matsushita K; Matsumoto K; Kimura Y; Miyamoto M; Ogawa H; Takamura T; Sugano T; Ishigami T; Uchino K; Kimura K; Umemura S
    J Cardiol; 2012 Oct; 60(4):301-5. PubMed ID: 22763383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
    Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
    J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjustments of heart failure medication after implantation of a cardiac resynchronization therapy defibrillator.
    Hitz L; Kühne MS; Sticherling C; Osswald S; Schaer BA
    Minerva Med; 2012 Oct; 103(5):361-7. PubMed ID: 23042371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy.
    Schmidt S; Hürlimann D; Starck CT; Hindricks G; Lüscher TF; Ruschitzka F; Steffel J
    Eur Heart J; 2014 Apr; 35(16):1051-60. PubMed ID: 24371079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of pre-implantation characteristics on long-term outcome.
    van Bommel RJ; Borleffs CJ; Ypenburg C; Marsan NA; Delgado V; Bertini M; van der Wall EE; Schalij MJ; Bax JJ
    Eur Heart J; 2010 Nov; 31(22):2783-90. PubMed ID: 20693544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac resynchronization therapy allows the optimization of medical treatment in heart failure patients.
    Kachboura S; Ben Halima A; Ibn Elhadj Z; Marrakchi S; Chrigui R; Kammoun I; Chine S; Lefi A
    Ann Cardiol Angeiol (Paris); 2014 Feb; 63(1):17-22. PubMed ID: 23932251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Drug Utilization and Outcome With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy.
    Penn J; Goldenberg I; McNitt S; Polonsky B; Ruwald MH; Zareba W; Moss AJ; Alexis JD
    J Card Fail; 2015 Jul; 21(7):541-7. PubMed ID: 25800548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
    Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
    Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate pharmacotherapy intensification after cardiac resynchronization therapy: incidence, characteristics, and impact.
    Ogawa K; Yamasaki H; Aonuma K; Otani M; Hattori A; Baba M; Yoshida K; Igarashi M; Nishina H; Suzuki K; Nogami A; Ieda M
    ESC Heart Fail; 2024 Aug; 11(4):1888-1899. PubMed ID: 38467476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.
    Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ
    Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy.
    Martens P; Verbrugge FH; Nijst P; Bertrand PB; Dupont M; Tang WH; Mullens W
    J Card Fail; 2017 Aug; 23(8):597-605. PubMed ID: 28284756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of hyponatremia as a predictor for adverse events in patients with heart failure receiving cardiac resynchronization therapy.
    Sharma AK; Vegh EM; Kandala J; Orencole M; Januszkiewicz L; Bose A; Miller A; Parks KA; Heist EK; Singh JP
    Am J Cardiol; 2014 Jul; 114(1):83-7. PubMed ID: 24852916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and morbidity in cardiac resynchronization patients: impact of lead position, paced left ventricular QRS morphology and other characteristics on long-term outcome.
    Jastrzebski M; Wilinski J; Fijorek K; Sondej T; Czarnecka D
    Europace; 2013 Feb; 15(2):258-65. PubMed ID: 23047489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.